COVID-19 Contact Study - Immunoreaction after possible SARS-CoV-2 / COVID-19 contact

Conditions

U07.1

Karsten Lürken, Anna Meinecke, Luis Manthey, Anne Cossmann, Metodi V. Stankov et al. (12 authors)

European journal of medical research2025-01-161 citations

10.1186/s40001-025-02274-3

Feasibility of self-organized blood sample collection in adults for study purposes in a primary care setting

Dominik Schröder, Frank Müller, Gloria Heesen, Eva Hummers, Alexandra Dopfer‐Jablonka et al. (11 authors)

PLoS ONE2023-05-2512 citations

10.1371/journal.pone.0286014

Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals.

Behrens GMN, Cossmann A, Stankov MV, Schulte B, Streeck H, Förster R, Bosnjak B, Willenzon S, Boeck AL, Thu Tran A, Thiele T, Graalmann T, Kayser MZ, Zychlinsky Scharff A, Dopfer C, Horke A, Pink I, Witte T, Wetzke M, Ernst D, Jablonka A, Happle C.

2020-09-0431 citations

10.1007/s40121-020-00334-1

Interventions

Group 1: This study has two phases. After informed consent phase 1 assesses longitudinally the seroconversion against SARS CoV-2 in departments with intensive patient contact, including COVID-19 patie

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: health care worker

Exclusion criteria

Exclusion criteria: no informed consent

Design outcomes

Primary

Measure	Time frame
Seroconversion (IgG) with quantitiative ELISA	—

Secondary

Measure	Time frame
Duration of immunoglobulin response range of immunoglobulin response respiratory symptoms cellular immunoreaction association to health care	—

Countries

Germany

Contacts

Public ContactGeorg Behrens

Medizinische Hochschule Hannover

behrens.georg@mh-hannover.de0511 532 5337

Outcome results

None listed